Open Nav

Please submit your session questions in advance at

AbMax Biotechnology CO., LTD

AbMax Biotechnology Co., Ltd. was established in 2006 and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%. AbMax, as a member of biomedical field in the capital scientific and technological condition platform, is the training base of BeijingNormalUniversity and also joins the Alliance of Bio-Box Outsourcing, China (ABO). AbMax also undertook a dozen government major research projects and established the largest pathogen antibody library for emerging/outbreaking infectious diseases in China.

  • Date:Tuesday, February 12
  • Time:9:45 AM - 10:00 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23335
  • Goal for Presentation:De-immunization of Humira
  • Company Website:
  • Company HQ City:Beijing
  • Company HQ Country:China
  • Total Amount Raised to Date, in All Rounds:1.73 Million
  • Year Founded:2012
  • Main Therapeutic Focus:Tools/Drug Development Support Tech
  • Lead Product in Development:De-immunogenicity Humira
  • Development Phase of Primary Product:Discovery
Le Sun
AbMax Biotechnology CO., LTD